Literature DB >> 3485480

Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome.

B K Pedersen, P Oxholm, R Manthorpe, V Andersen.   

Abstract

Natural Killer (NK) cell activity against K562 target cells was measured in 21 female patients with primary Sjögren's syndrome (primary SS) and in 20 female normal controls matched for age. The in vitro effect of alpha-interferon (IF) and interleukin 2 (IL-2) on NK cell activity was examined and the percentage of large granular lymphocytes (LGL) in blood was measured. Median baseline NK cell activity in primary SS was 15.4% versus 24.4% in the controls (P less than 0.05). Median IF-enhanced NK cell activity in the SS group was 35.5% versus 49.6% in the controls (P less than 0.02). IL-2-enhanced NK cell activity was 35.5% versus 37.6% in the controls (n.s.) The proportion of LGL did not differ in the two groups. Median LGL/lymphocytes was 4.0% in the primary SS patients versus 4.5% in the controls (n.s.). We conclude that the defective NK cell activity in patients with primary SS is functional, as the number of LGL is normal. Further the NK cell activity off SS was restored by IL-2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485480      PMCID: PMC1577338     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  The effect of monensin on the antibody-dependent cell-mediated killing.

Authors:  B Pedersen; B Norrild; H J Krebs
Journal:  Cell Immunol       Date:  1982-09-01       Impact factor: 4.868

2.  Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  N Miyasaka; T Nakamura; I J Russell; N Talal
Journal:  Clin Immunol Immunopathol       Date:  1984-04

3.  Natural killing activity in Sjögren's syndrome. An analysis of defective mechanisms.

Authors:  N Miyasaka; W Seaman; A Bakshi; B Sauvezie; V Strand; R Pope; N Talal
Journal:  Arthritis Rheum       Date:  1983-08

4.  Interleukin 2 augmentation of natural killer cell activity in homosexual men with acquired immune deficiency syndrome.

Authors:  M M Reddy; N Pinyavat; M H Grieco
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

5.  Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells.

Authors:  A Rey; B Klein; D Zagury; C Thierry; B Serrou
Journal:  Immunol Lett       Date:  1983-03       Impact factor: 3.685

6.  Azathioprine as single drug in the treatment of rheumatoid arthritis induces complete suppression of natural killer cell activity.

Authors:  B K Pedersen; J M Beyer; A Rasmussen; K Klarlund; K Hørslev-Petersen; B N Pedersen; P Helin
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1984-08

7.  Interleukin 2 dependence of human natural killer (NK) cell activity.

Authors:  W Domzig; B M Stadler; R B Herberman
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

8.  Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor.

Authors:  T Kasahara; J Y Djeu; S F Dougherty; J J Oppenheim
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

9.  Severe acquired immunodeficiency in European homosexual men.

Authors:  J Gerstoft; A Malchow-Møller; I Bygbjerg; E Dickmeiss; C Enk; P Halberg; S Haahr; M Jacobsen; K Jensen; J Mejer; J O Nielsen; H K Thomsen; J Søndergaard; I Lorenzen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-03

10.  Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

Authors:  A Mazumder; S A Rosenberg
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Natural killer cells and autoimmunity.

Authors:  E Grunebaum; E Malatzky-Goshen; Y Shoenfeld
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Inhibition of human natural killer cell activity by Legionella pneumophila protease.

Authors:  C Rechnitzer; M Diamant; B K Pedersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-11       Impact factor: 3.267

3.  Impaired release of natural killer cytotoxic factor in patients with primary Sjögren's syndrome.

Authors:  B K Pedersen; P Oxholm
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

4.  Inhibition of human natural killer cell activity by Pseudomonas aeruginosa alkaline protease and elastase.

Authors:  B K Pedersen; A Kharazmi
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

5.  Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes.

Authors:  N J Struyf; H W Snoeck; C H Bridts; L S De Clerck; W J Stevens
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

6.  The effect of ranitidine on cellular immunity in patients with multiple myeloma.

Authors:  H J Nielsen; H Nielsen; F Moesgaard; N Tvede; K Klarlund; B Mansa; A Drivsholm
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Depressed natural killer cell activity in acute myocardial infarction.

Authors:  K Klarlund; B K Pedersen; T G Theander; V Andersen
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.